TELA Bio, Inc.: management transactions · United States · SEC (Form 4)

About TELA Bio, Inc.

TELA Bio, Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States. The company focuses on innovative soft-tissue reconstruction solutions designed to support surgical repair and reconstruction while prioritizing preservation of the patient’s own anatomy. Headquartered in Malvern, Pennsylvania, TELA Bio is primarily commercial in the U.S. market, with a smaller international footprint. ([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-reports-fourth-quarter-and-full-year-2025-financial/)) Founded in 2012, the company was built around a biomaterials platform for soft-tissue reconstruction. Its portfolio originally centered on abdominal wall reconstruction and hernia repair, and later expanded into plastic and reconstructive surgery. Key products include OviTex, used in soft-tissue reconstruction and hernia repair, and OviTex PRS, aimed at plastic and reconstructive surgery applications. TELA Bio has also secured FDA 510(k) clearances for product families such as Restella and for certain OviTex PRS configurations, which have supported broader commercial adoption. ([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-announces-510k-clearance-ovitexr-prs-long-term)) From a competitive standpoint, TELA Bio is a specialized player rather than a large diversified medtech platform. Its differentiation comes from the combination of biomaterial design, clinical evidence, and a focused commercial model targeting hospital-based surgeons. In the highly competitive soft-tissue reconstruction market, the company is seeking share gains through product performance, expanded sizes/configurations, and deeper commercial penetration. At the same time, the business remains exposed to the usual medtech risks: reimbursement dynamics, clinical adoption, pricing pressure, the need for ongoing evidence generation, and sustained sales-force investment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm)) Recent developments point to growth momentum, but also to a business that is not yet profitable. In the second quarter of 2025, TELA Bio reported revenue of $20.2 million, up 26% year over year, with particularly strong growth in OviTex PRS. In March 2026, the company said it closed 2025 with its strongest quarterly revenue on record at $20.9 million in Q4 2025, while keeping operating expenses essentially flat for the year. In early 2026, management also announced a strategic board refresh aimed at accelerating growth and supporting the path to profitability. For investors, TELA Bio remains a niche medtech growth name on the NASDAQ, with attractive commercial potential but continuing execution and profitability risk. ([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-reports-second-quarter-2025-financial-results))